{"entity":{"id":"hitap","kind":"institution","name":"Health Intervention and Technology Assessment Program (HITAP)","aka":["HITAP","โครงการประเมินเทคโนโลยีและนโยบายด้านสุขภาพ","HITAP Foundation"],"tldr":"Thailand's health technology assessment programme. Its cost-effectiveness research is part of how Thailand decides what the public schemes pay for, including the National List of Essential Medicines, which in 2013 screened medicines against a value of 160,000 baht per quality-adjusted life year.","summary":"The Health Intervention and Technology Assessment Program is a health technology assessment body based at the Department of Health building of the Ministry of Public Health on Tiwanon Road, Nonthaburi, operating as the HITAP Foundation. A 2009 history by its researchers describes how demands to add expensive technologies to the public benefit package after 2006 made health technology assessment part of national policy decisions, with HITAP's work as the illustration.\n\nIts 2015 policy brief states that the value per quality-adjusted life year used by the subcommittee for the National List of Essential Medicines in 2013 was 160,000 baht, about 1.2 times gross national income per head, and reports a 2012 survey of 4,320 people in 11 provinces in which Thais were willing to pay 195,000 to 325,000 baht for a year of life gained but 113,000 to 156,000 baht for a gain in quality of life alone. A 2026 comparison of cancer medicine lists describes Thailand's route as a technical-negotiation model, using assessment-informed selection and price negotiation.\n\nThe coordinates are the centroid of Mueang Nonthaburi district, not the street address. Whether the 160,000 baht figure has changed since the 2015 brief was not verified.","asOf":"2026-11-04","links":[{"label":"HITAP policy brief: What is the value of a QALY and how much is it? (July 2015, PDF)","url":"https://www.hitap.net/wp-content/uploads/2014/12/PB_20-WTP-Eng-Final-for-web.pdf"},{"label":"Teerawattananon et al., Historical development of health technology assessment in Thailand (2009)","url":"https://doi.org/10.1017/S0266462309090709"},{"label":"HITAP","url":"https://www.hitap.net/en/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["thai-fda","nhso-thailand"],"pathways":[],"terms":["hta"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-vargas-who-eml-cancer-chile-kenya-thailand-2026"],"journals":[],"dependsOn":[],"notes":[],"city":"Nonthaburi","country":"TH","lat":13.86,"lng":100.51,"institutionType":"research-institute","website":"https://www.hitap.net","programs":["Economic evaluation for the National List of Essential Medicines","Benefit package assessments for the Universal Coverage Scheme","Willingness-to-pay per QALY research"]},"route":"/institutions/hitap/","neighbours":{"institution":[{"id":"thai-fda","kind":"institution","name":"Food and Drug Administration, Thailand","route":"/institutions/thai-fda/"},{"id":"nhso-thailand","kind":"institution","name":"National Health Security Office, Thailand","route":"/institutions/nhso-thailand/"}],"term":[{"id":"hta","kind":"term","name":"Health technology assessment (HTA), reimbursement and QALYs","route":"/terms/hta/"}],"paper":[{"id":"paper-vargas-who-eml-cancer-chile-kenya-thailand-2026","kind":"paper","name":"Best practices for implementing the WHO Model List of Essential Cancer Medicines: Chile, Kenya, and Thailand","route":"/key-papers/paper-vargas-who-eml-cancer-chile-kenya-thailand-2026/"}]}}